SUMMARY OF CONCLUSIONS FROM A CONSENSUS PANEL OF EXPERTS ON THE IMPORTANCE OF RIVAROXABAN IN THE MANAGEMENT OF PATIENTS RECOVERING FROM ACUTE CORONARY SYNDROME
M. Ya. Ruda,
A. I. Syrkin,
E. P. Panchenko,
I. S. Yavelov,
O. V. Averkov,
R. M. Shahnovich,
A. L. Komarov
Affiliations
M. Ya. Ruda
Myasnikov Cardiology Institute RK NPK of the Ministry of Health of the Russian Federation
A. I. Syrkin
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
E. P. Panchenko
Myasnikov Cardiology Institute RK NPK of the Ministry of Health of the Russian Federation
I. S. Yavelov
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
O. V. Averkov
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
R. M. Shahnovich
Filatov City Clinical Hospital No. 15 of the Moscow Health Department, Department of Internal Medicine FPK MR RUDN
A. L. Komarov
Институт кардиологии им. А.Л. Мясникова ФГБУ РКНПК МЗ РФ
Despite the widespread introduction of primary percutaneous coronary interventions (PCI) and the use of new powerful antiplatelet drugs for the management of patients with acute coronary syndrome (ACS) at high risk, the relapse rate of coronary events associated with atherothrombosis remains sufficiently high. In the CURE [1] study the prevalence of myocardial infarction (MI), cere-brovascular accident (CVA) and cardiovascular death (CVD) among patients with ACS without ST elevation, who received aspirin and clopidogrel within 12 months, was 9.3%, and in the PLATO [2] study the frequency of above complications in a group of high-risk patients with ACS, who received a new P2Y12 inhibitor tikagrelor, amounted to 9.8%.
